Liver Injury Indicating Fatty Liver but Not Serologic NASH Marker Improves under Metformin Treatment in Polycystic Ovary Syndrome
Joint Authors
Gerken, Guido
Tan, Susanne
Vollmar, Nils
Benson, Sven
Sowa, Jan-Peter
Fuhrer, Dagmar
Canbay, Ali
Bechmann, Lars P.
Source
International Journal of Endocrinology
Issue
Vol. 2015, Issue 2015 (31 Dec. 2015), pp.1-9, 9 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2015-03-19
Country of Publication
Egypt
No. of Pages
9
Main Subjects
Abstract EN
Objective.
Polycystic ovary syndrome (PCOS) is associated with obesity and insulin resistance (IR), key features of nonalcoholic steatohepatitis (NASH).
Cytokeratin 18 fragments (M30) have been established as a serum marker for NASH.
The insulin sensitizer metformin improves hepatic IR.
This study evaluates the influence of MF on serologic NASH (sNASH) in patients with PCOS.
Patients and Methods.
In 89 patients, metabolic parameters, liver injury indicating fatty liver (LIFL), and M30 were assessed at baseline and after metformin treatment.
Patients with initial IR were subdivided into dissolved (PCOS-exIR) and persistent IR (PCOS-PIR) after treatment and compared to an initially insulin sensitive PCOS group (PCOS-C).
Results.
Improvement of LIFL prevalence could be seen in PCOS-C and PCOS-exIR compared to PCOS-PIR (−19.4, resp., −12.0% versus 7.2%, Chi2 = 29.5, P < 0.001 ) without change in sNASH prevalence.
In PCOS-PIR, ALT levels increased significantly accompanied by a nominal, nonsignificant M30 increase.
Conclusions.
Metformin improves LIFL in subgroups of patients with PCOS without influencing sNASH.
This could either indicate a missing effect of metformin on NAFLD or slowed disease progression.
Further studies are needed to elucidate NAFLD in the context of PCOS and potential therapeutic options.
American Psychological Association (APA)
Tan, Susanne& Vollmar, Nils& Benson, Sven& Sowa, Jan-Peter& Bechmann, Lars P.& Gerken, Guido…[et al.]. 2015. Liver Injury Indicating Fatty Liver but Not Serologic NASH Marker Improves under Metformin Treatment in Polycystic Ovary Syndrome. International Journal of Endocrinology،Vol. 2015, no. 2015, pp.1-9.
https://search.emarefa.net/detail/BIM-1065608
Modern Language Association (MLA)
Tan, Susanne…[et al.]. Liver Injury Indicating Fatty Liver but Not Serologic NASH Marker Improves under Metformin Treatment in Polycystic Ovary Syndrome. International Journal of Endocrinology No. 2015 (2015), pp.1-9.
https://search.emarefa.net/detail/BIM-1065608
American Medical Association (AMA)
Tan, Susanne& Vollmar, Nils& Benson, Sven& Sowa, Jan-Peter& Bechmann, Lars P.& Gerken, Guido…[et al.]. Liver Injury Indicating Fatty Liver but Not Serologic NASH Marker Improves under Metformin Treatment in Polycystic Ovary Syndrome. International Journal of Endocrinology. 2015. Vol. 2015, no. 2015, pp.1-9.
https://search.emarefa.net/detail/BIM-1065608
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1065608